Abstract
Gene fusions involving NTRK1, NTRK2 and NTRK3 are oncogenic drivers across a wide variety of cancer types. Inhibitors of the chimeric TRKA/B/C protein kinases encoded by these fusions are now avail...
Funding Information
  • GD Demetri
  • G1 Therapeutics
  • Caris Life Sciences
  • ERASCA Pharmaceuticals
  • Champions Oncology
  • National Institutes of Health

This publication has 40 references indexed in Scilit: